While direct evidence on leptin sensitizers specifically in COPD is limited, the modulation of leptin levels by GLP-1RAs suggests a potential pathway for reducing inflammation and improving immune function in COPD patients [297]. This evidence concerns the gene LEP and chronic obstructive pulmonary disease.